| __timestamp | BioCryst Pharmaceuticals, Inc. | Rhythm Pharmaceuticals, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 7461000 | 1213000 |
| Thursday, January 1, 2015 | 13047000 | 3425000 |
| Friday, January 1, 2016 | 11253000 | 6311000 |
| Sunday, January 1, 2017 | 13933000 | 9518000 |
| Monday, January 1, 2018 | 29514000 | 28080000 |
| Tuesday, January 1, 2019 | 37121000 | 36550000 |
| Wednesday, January 1, 2020 | 67929000 | 46125000 |
| Friday, January 1, 2021 | 118818000 | 68486000 |
| Saturday, January 1, 2022 | 159371000 | 92032000 |
| Sunday, January 1, 2023 | 213894000 | 117532000 |
Igniting the spark of knowledge
In the competitive world of biotechnology, managing operational costs is crucial. This analysis compares the Selling, General, and Administrative (SG&A) expenses of Rhythm Pharmaceuticals, Inc. and BioCryst Pharmaceuticals, Inc. from 2014 to 2023. Over this period, BioCryst's SG&A expenses surged by nearly 2,800%, peaking in 2023. Rhythm Pharmaceuticals also saw a significant increase, with expenses rising by approximately 9,600% over the same period. Notably, both companies experienced their most substantial growth in SG&A expenses between 2020 and 2023, reflecting strategic investments in marketing and administration. This trend highlights the growing financial commitments these companies are making to support their innovative drug pipelines. As the biotech industry continues to evolve, understanding these financial dynamics offers valuable insights into the strategic priorities of leading firms.
Cost Management Insights: SG&A Expenses for Sanofi and Rhythm Pharmaceuticals, Inc.
Comparing SG&A Expenses: Zoetis Inc. vs Rhythm Pharmaceuticals, Inc. Trends and Insights
Cost Management Insights: SG&A Expenses for Viatris Inc. and BioCryst Pharmaceuticals, Inc.
Selling, General, and Administrative Costs: Exelixis, Inc. vs BioCryst Pharmaceuticals, Inc.
Cost Management Insights: SG&A Expenses for Ultragenyx Pharmaceutical Inc. and BioCryst Pharmaceuticals, Inc.
Research and Development Expenses Breakdown: Rhythm Pharmaceuticals, Inc. vs BioCryst Pharmaceuticals, Inc.
Breaking Down SG&A Expenses: Rhythm Pharmaceuticals, Inc. vs Taro Pharmaceutical Industries Ltd.
Operational Costs Compared: SG&A Analysis of ACADIA Pharmaceuticals Inc. and BioCryst Pharmaceuticals, Inc.
SG&A Efficiency Analysis: Comparing Arrowhead Pharmaceuticals, Inc. and BioCryst Pharmaceuticals, Inc.
ImmunityBio, Inc. vs BioCryst Pharmaceuticals, Inc.: SG&A Expense Trends
Who Optimizes SG&A Costs Better? Dynavax Technologies Corporation or BioCryst Pharmaceuticals, Inc.
Selling, General, and Administrative Costs: Travere Therapeutics, Inc. vs BioCryst Pharmaceuticals, Inc.